Headshot of Lewis Cantley

Lewis Cantley, Ph.D.

Professor of Cell Biology (HMS)
Dana-Farber Cancer Institute
TBA--

Lew Cantley is widely known for his many seminal discoveries in signaling and metabolism, including the identification of PI3 kinase and its role in transformation, as well as groundbreaking work unraveling the complexities of protein kinase signaling--his work has had major impact across virtually every aspect of cancer cell biology. For those of you who are new to the department, Lew was a Cell Bio faculty member from 1992-2003 before transitioning to the then newly formed HMS Department of Systems Biology in 2003. In 2012, Lew was recruited to Weill Cornell in New York City, where he served as Director of the Meyer Cancer Center. There, he built a remarkable program focused on the intersection of metabolism and signaling in cancer.

Lew rejoined the Department of Cell Biology at HMS and the DFCI-Cancer Cell Biology in 2022.  

Dana Farber Cancer Institute

Cancer Cell Biology

Faculty Assistant

p85a SH2 domain phosphorylation by IKK promotes feedback inhibition of PI3K and Akt in response to cellular starvation.
Authors: Authors: Comb WC, Hutti JE, Cogswell P, Cantley LC, Baldwin AS.
Mol Cell
View full abstract on Pubmed
Breathless cancer cells get fat on glutamine.
Authors: Authors: Anastasiou D, Cantley LC.
Cell Res
View full abstract on Pubmed
Somatic mutations of PIK3R1 promote gliomagenesis.
Authors: Authors: Quayle SN, Lee JY, Cheung LW, Ding L, Wiedemeyer R, Dewan RW, Huang-Hobbs E, Zhuang L, Wilson RK, Ligon KL, Mills GB, Cantley LC, Chin L.
PLoS One
View full abstract on Pubmed
Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses.
Authors: Authors: Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, Shen M, Bellinger G, Sasaki AT, Locasale JW, Auld DS, Thomas CJ, Vander Heiden MG, Cantley LC.
Science
View full abstract on Pubmed
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Authors: Authors: Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, Settleman J, Wong KK, Cantley LC, Engelman JA.
J Clin Invest
View full abstract on Pubmed
Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer.
Authors: Authors: Yang X, Turke AB, Qi J, Song Y, Rexer BN, Miller TW, Jänne PA, Arteaga CL, Cantley LC, Engelman JA, Asara JM.
Cancer Res
View full abstract on Pubmed
Metabolic regulation of protein N-alpha-acetylation by Bcl-xL promotes cell survival.
Authors: Authors: Yi CH, Pan H, Seebacher J, Jang IH, Hyberts SG, Heffron GJ, Vander Heiden MG, Yang R, Li F, Locasale JW, Sharfi H, Zhai B, Rodriguez-Mias R, Luithardt H, Cantley LC, Daley GQ, Asara JM, Gygi SP, Wagner G, Liu CF, Yuan J.
Cell
View full abstract on Pubmed
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.
Authors: Authors: Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB.
Cancer Discov
View full abstract on Pubmed
Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling.
Authors: Authors: Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, Villén J, Kubica N, Hoffman GR, Cantley LC, Gygi SP, Blenis J.
Science
View full abstract on Pubmed
Characterization of KRAS rearrangements in metastatic prostate cancer.
Authors: Authors: Wang XS, Shankar S, Dhanasekaran SM, Ateeq B, Sasaki AT, Jing X, Robinson D, Cao Q, Prensner JR, Yocum AK, Wang R, Fries DF, Han B, Asangani IA, Cao X, Li Y, Omenn GS, Pflueger D, Gopalan A, Reuter VE, Kahoud ER, Cantley LC, Rubin MA, Palanisamy N, Varambally S, Chinnaiyan AM.
Cancer Discov
View full abstract on Pubmed